TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23485887

Group type: EXPERIMENTAL
Intervention: Very low protein diet (VLPD; 0.3 g/kg bw/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low protein diet (LPD; 0.6 g/kg bw/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hemodialysis patients (HD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chronic kidney disease (CKD) patients
Number of subjects: 32
Study: 21599433

Group type: EXPERIMENTAL
Intervention: Deferiprone 75 mg/kg 4 days/week and DFO 50 mg/kg/day for 3 days/week
Number of subjects: 213

Group type: COMPARATOR
Intervention: Deferiprone alone 75 mg/kg 7 days/week
Number of subjects: 213
Study: 19439117

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (target group, blood glucose 6.2 to 8.3 mmol/L)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Routine insulin therapy (routine group, blood glucose 4.1 to 6.1 mmol/L)
Number of subjects: 27
Study: 17012299

Group type: EXPERIMENTAL
Intervention: 20 mg/day rosuvastatin therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 35
Study: 15138798

Group type: EXPERIMENTAL
Intervention: Calcium-alginate insert with 0% hydroxyethylcellulose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calcium-alginate insert with 5% hydroxyethylcellulose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calcium-alginate insert with 30% hydroxyethylcellulose
Number of subjects: 24
Study: 11319198

Group type: EXPERIMENTAL
Intervention: HAPE-susceptible subjects
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HAPE-susceptible subjects with HAPE
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HAPE-susceptible subjects without HAPE
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study: 9272760

Group type: EXPERIMENTAL
Intervention: Antioxidant treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Site raters
Number of subjects: 45
Study: 8509525

Group type: EXPERIMENTAL
Intervention: Nortriptyline (12-week placebo-controlled, double-blind trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (12-week placebo-controlled, double-blind trial)
Number of subjects: 0
Study: 31096099

Group type: EXPERIMENTAL
Intervention: High mean arterial pressure (MAP) target ≥ 85 mmHg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low mean arterial pressure (MAP) target 65-70 mmHg
Number of subjects: 18
Study: 29927398

Group type: EXPERIMENTAL
Intervention: Cytoflavin (2 tablets 2 times a day)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Basic therapy (Control)
Number of subjects: 156
Study: 26733479

Group type: EXPERIMENTAL
Intervention: Vitamin D3 20,000 IU per week for 12 months
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study: 25077847

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Number of subjects: 10633

Group type: COMPARATOR
Intervention: Non-MBCT group therapy
Number of subjects: 10633
Study: 22284022

Group type: EXPERIMENTAL
Intervention: Treatment with varying levels of depressive symptoms (NO, SLOW, GO)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Baseline CDRS-R scores
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Baseline functioning
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Baseline CDRS and MRS scores
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MRS scores over time
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Increasing MRS scores
Number of subjects: 72
Study: 22049891

Group type: EXPERIMENTAL
Intervention: Gargling with ketamine 50 mg in drinking water 30 ml for 30 s, 5 min before induction of anaesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gargling with drinking water 30 ml
Number of subjects: 40
Study: 18949039

Group type: EXPERIMENTAL
Intervention: Grouping search algorithm
Number of subjects: 0
Study: 15753530

Group type: EXPERIMENTAL
Intervention: Zinc supplement of 25 mg daily for 14 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 14608136

Group type: EXPERIMENTAL
Intervention: Intracoronary beta radiation (90Strontium/90Yttrium)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 10569419

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg BID for 3-8 days preoperatively
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg BID for 9-14 days preoperatively
Number of subjects: 20
Study: 9059267

Group type: EXPERIMENTAL
Intervention: Radiotherapy (10, 12, or 15 Gy of 6 MV photons)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (non-randomised observation)
Number of subjects: 41
Study: 1724941

Group type: EXPERIMENTAL
Intervention: Enteral nutrition supplemented with arginine, menhaden oil, and RNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutritionally complete enteral formula (control)
Number of subjects: 0
Study: 6349560

Group type: EXPERIMENTAL
Intervention: Combined group A and group C meningococcal polysaccharide vaccine
Number of subjects: 438

Group type: COMPARATOR
Intervention: Control group (not vaccinated)
Number of subjects: 438
Study: 30855463

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.2 μg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.1 μg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.05 μg/kg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sufentanil 0 μg/kg (control group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.15 μg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sufentanil (all dosages)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 75
Study: 27609065

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26757356

Group type: EXPERIMENTAL
Intervention: Pedometer-based walking intervention for 12 weeks, increasing walking distance by 500 steps per week
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 112
Study: 24314857

Group type: EXPERIMENTAL
Intervention: Warm saline mouth rinse six times daily (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Warm saline mouth rinse twice daily (Group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No saline mouth rinse (Group C)
Number of subjects: 120
Study: 21508663

Group type: EXPERIMENTAL
Intervention: Phosphorous magnetic resonance spectroscopy (31P MRS)
Number of subjects: 15
Study: 19308417

Group type: EXPERIMENTAL
Intervention: MR spectroscopy (MRS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Magnetisation transfer imaging (MTI)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (treatment initiation)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: NAWM
Number of subjects: 17
Study: 17279280

Group type: EXPERIMENTAL
Intervention: Nutritional guidance in the first year of life with monthly follow‐up home visits
Number of subjects: 369

Group type: COMPARATOR
Intervention: Control group with visits at 6 and 12 months, without nutritional intervention
Number of subjects: 369
Study: 15599697

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 637

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637
Study: 11368699

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2064
Study: 9852628

Group type: EXPERIMENTAL
Intervention: Germinated barley foodstuff (GBF) 30 g/day for 28 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Germinated barley foodstuff (GBF)
Number of subjects: 10
Study: 7991338

Group type: EXPERIMENTAL
Intervention: Field sobriety tests
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal-abilities tests
Number of subjects: 14
Study: 2465457

Group type: EXPERIMENTAL
Intervention: Aprotinin (700 mg approximately)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study: 31619112

Group type: EXPERIMENTAL
Intervention: Auditory-perceptual ratings of vocal tremor severity by 4 female audiologists on a continuous 10-cm scale.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Acoustic markers of vocal tremor including 12 acoustic measures of rate, extent and perturbation of fundamental frequency (f0), and intensity level (IL) modulation.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Acoustic model of vocal tremor severity based on the 12 acoustic measures.
Number of subjects: 56
Study: 27911869

Group type: EXPERIMENTAL
Intervention: TOF regimen (paclitaxel 135 mg/m2 iv on day 1, oxaliplatin 100 mg/m2 iv on day 1, fluorouracil 500 mg/m2 continuous iv on day 1-5)
Number of subjects: 60

Group type: COMPARATOR
Intervention: SOX regimen (oxaliplatin 130 mg/m2 iv on day 1, S-1 40 mg/60mg orally twice/day on days 1-14)
Number of subjects: 60
Study: 25387728

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for 12 months
Number of subjects: 424

Group type: COMPARATOR
Intervention: Successful aging education group (control)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 424
Study: 23307011

Group type: EXPERIMENTAL
Intervention: 2MVCs performed immediately (0d) before MaxECC
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 2MVCs performed 2 days (2d) before MaxECC
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 2MVCs performed 4 days (4d) before MaxECC
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no 2MVCs)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 2MVCs performed 7 days (7d) before MaxECC
Number of subjects: 65
Study: 21300736

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta‐1a (IFNβ‐1a) treatment
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 19889831

Group type: EXPERIMENTAL
Intervention: PRK with 0.002% MMC for 1 min
Number of subjects: 44

Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 44
Study: 16864757

Group type: EXPERIMENTAL
Intervention: 0.3 mg of recombinant human thyrotropin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 12749545

Group type: COMPARATOR
Intervention: Driving after controlled habitual sleep (8.5 hours) (Road 1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Driving after reduced sleep (2 hours) (Road 2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Laboratory after controlled habitual sleep (8.5 hours)
Number of subjects: 10
Study: 11019779

Group type: EXPERIMENTAL
Intervention: Intervention group (free day care, rehab program, mood induction interventions)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 260
Study: 8791047

Group type: EXPERIMENTAL
Intervention: 3 months of neo‐adjuvant treatment with triptorelin (3.75 mg i.m. every 28 days) and cyproterone acetate (50 mg b.i.d. for 3 weeks)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Immediate radical prostatectomy
Number of subjects: 111
Study: 1455326

Group type: EXPERIMENTAL
Intervention: Ibuprofen (Ibumetin)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paracetamol/codeine combination (Citodon)
Number of subjects: 120
Study: 2861220

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Astemizole + Beclomethasone dipropionate
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 55
Study: 29991375

Group type: EXPERIMENTAL
Intervention: Cost-offset community-supported agriculture (CO-CSA) program
Number of subjects: 53
Study: 28881347

Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (500 mg capsules, 2 capsules daily for 12 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (2 placebo capsules daily for 12 weeks)
Number of subjects: 61
Study: 26216378

Group type: EXPERIMENTAL
Intervention: Nebulized fluticasone propionate (2000 mcg/day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Oral methylprednisolone (1 mg/kg/day)
Number of subjects: 81
Study: 23713756

Group type: EXPERIMENTAL
Intervention: HR‐VG (Healthy Relationships via video-group)
Number of subjects: 4
Study: 21272339

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once daily for 52 weeks
Number of subjects: 2686

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2686
Study: 18764946

Group type: EXPERIMENTAL
Intervention: Slim Fast Plan
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Weight Watchers Pure Points Programme
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Dr Atkins' New Diet Revolution
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Rosemary Conley's 'Eat Yourself Slim' Diet & Fitness Plan
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 293
Study: 16562650

Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant radiation therapy combined with chemotherapy
Number of subjects: 0
Study: 12706932

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogen (CEE) (0.625 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Transdermal estradiol (E(2)) (100 microg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 10675209

Group type: EXPERIMENTAL
Intervention: New rapid diagnostic methods for TBM, details not available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy for TBM, duration not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant corticosteroids for TBM, details not available
Number of subjects: 0
Study: 9586515

Group type: EXPERIMENTAL
Intervention: Michigan splint therapy for two months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no active treatment)
Number of subjects: 40
Study: 8246258

Group type: COMPARATOR
Intervention: E. coli O157 agglutinating antibodies
Number of subjects: 121

Group type: COMPARATOR
Intervention: IgG antibodies against whole intact E. coli O157 cells
Number of subjects: 121

Group type: COMPARATOR
Intervention: Faecal IgA specific for E. coli O157
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Follow-up faecal samples
Number of subjects: 121
Study: 3542383

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy for breast cancer
Number of subjects: 113
Study: 30545125

Group type: EXPERIMENTAL
Intervention: MyNutriCart app
Number of subjects: 51

Group type: COMPARATOR
Intervention: Traditional group (face-to-face counseling)
Number of subjects: 51
Study: 27354079

Group type: EXPERIMENTAL
Intervention: Communication skills training (CST) intervention with a survivorship planning consultation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm with time-controlled, manualised wellness rehabilitation consultation focused on healthy nutrition and exercise post-chemotherapy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Communication skills training (CST) intervention.
Number of subjects: 0
Study: 24231668

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 39
Study: 23468100

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of alcohol, clamped at a steady-state breath alcohol (BrAC) concentration of 60 mg/dL
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo saline infusion
Number of subjects: 40
Study: 21543294

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Amiodarone plus n-3 polyunsaturated fatty acids
Number of subjects: 47
Study: 18714627

Group type: EXPERIMENTAL
Intervention: Screen-based simulation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional lectures
Number of subjects: 64
Study: 16585985

Group type: EXPERIMENTAL
Intervention: Topical methyl aminolevulinate photodynamic therapy (160 mg/g cream applied for 3 h prior to illumination by non‐coherent red light at 570‐670 nm, light dose 75 J/cm2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Topical methyl aminolevulinate photodynamic therapy
Number of subjects: 27
Study: 12669898

Group type: EXPERIMENTAL
Intervention: Daily ASA treatment after ASA desensitization
Number of subjects: 38
Study: 10896012

Group type: EXPERIMENTAL
Intervention: Squat technique with 0 kg load
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Squat technique with 1 kg load
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Squat technique with 3 kg load
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stoop technique
Number of subjects: 20
Study: 9138436

Group type: EXPERIMENTAL
Intervention: Clonidine (1.5 micrograms/kg Catapres)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Droperidol (15 micrograms/kg Droleptan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1303336

Group type: EXPERIMENTAL
Intervention: Ivermectin 0.1 mg/kg orally at a single dose
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Ivermectin 0.2 mg/kg orally at a single dose
Number of subjects: 166

Group type: COMPARATOR
Intervention: Pyrantel pamoate 10 mg/kg orally at a single dose
Number of subjects: 166
Study: 3512031

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (heparin fragment) 5000 anti-factor Xa units once daily
Number of subjects: 432

Group type: COMPARATOR
Intervention: Conventional low-dose heparin 5000 units twice daily
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (heparin fragment)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Conventional low-dose heparin
Number of subjects: 432
Study: 30089234

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the rVLPFC
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 96
Study: 27771800

Group type: EXPERIMENTAL
Intervention: High-Power Overreaching Protocol (HPOR)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-Intensity Overtraining Protocol (HIOT)
Number of subjects: 14
Study: 24853888

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation from 1 to 9 months
Number of subjects: 0
Study: 22367654

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 20657084

Group type: EXPERIMENTAL
Intervention: Open flap debridement plus Bioplant HTR
Number of subjects: 5

Group type: COMPARATOR
Intervention: Open debridement alone
Number of subjects: 5
Study: 18499363

Group type: EXPERIMENTAL
Intervention: Anthropometric status (weight-for-age, height-for-age, mid-upper arm circumference, head circumference)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Socioeconomic status
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Kilifi Developmental Inventory (psychomotor functioning assessment)
Number of subjects: 204
Study: 19444658

Group type: EXPERIMENTAL
Intervention: Regimen 1 - OPTIFREE EXPRESS MPDS (polyquaternium‐1 0.001% and myristamidopropyl dimethylamine 0.0005%)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Regimen 1 - OPTIFREE EXPRESS MPDS
Number of subjects: 111

Group type: COMPARATOR
Intervention: Regimen 2 - ReNu MultiPLUS MPS (polyhexamethylene biguanide 0.0001%)
Number of subjects: 111
Study: 16381629

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 200 microg every 2 weeks
Number of subjects: 141

Group type: COMPARATOR
Intervention: Epoetin alfa 40,000 U weekly
Number of subjects: 141
Study: 11502918

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for 28 days, followed by 10 mg/day)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 286
Study: 9972057

Group type: EXPERIMENTAL
Intervention: Western blot analysis in patients with Lyme borreliosis
Number of subjects: 48

Group type: COMPARATOR
Intervention: Western blot analysis in controls
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Western blot analysis in patients with erythema migrans and Lyme arthritis
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Western blot analysis in neuroborreliosis patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined analysis of Western blot results (IgM/IgG)
Number of subjects: 48
Study: 8072708

Group type: EXPERIMENTAL
Intervention: mini‐tracheotomy postoperatively
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no mini‐tracheotomy)
Number of subjects: 20
Study: 3392552

Group type: EXPERIMENTAL
Intervention: r-metHuIFN-Con1 at 30 mcg/m2/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: r-metHuIFN-Con1 at 45 mcg/m2/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: r-metHuIFN-Con1
Number of subjects: 21
Study: 30415602

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17160
Study: 29939055

Group type: EXPERIMENTAL
Intervention: Cumulative habituation across treatment
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Fear activation, fear variability, and nonhabituation fear decreases
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Higher peak fear during nonhabituation exposures
Number of subjects: 111
Study: 27289566

Group type: EXPERIMENTAL
Intervention: 30% decline in circulating tumor cell (CTC) count after treatment
Number of subjects: 486

Group type: COMPARATOR
Intervention: Stable CTC count (<30% fall or <30% increase)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: CTC declines
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: 30% CTC decline after treatment from an initial count ≥5 cells/7.5 ml
Number of subjects: 486
Study: 24465958

Group type: EXPERIMENTAL
Intervention: Disclosure intervention (informed about objective compliance monitoring)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Reminder intervention (use of acoustical reminders)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Objective compliance
Number of subjects: 64
Study: 22151005

Group type: EXPERIMENTAL
Intervention: High-dose (HD) hydrocortisone regimen (30 mg daily) for 2 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-dose (LD) hydrocortisone regimen (17.5 mg daily) for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 10